New Drugs Could Save Thousands of Obese Americans Each Year

Imagine if a group of drugs could help Americans lose significant weight and reduce the risk of deadly diseases. Two recent medications, semaglutide (found in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), are showing promising results. A study published in the journal PNAS suggests these drugs could save thousands of lives annually by tackling obesity and type 2 diabetes. Before becoming famous for weight loss, these drugs were used to treat diabetes. Now, trials show they can slash the risk of heart disease and kidney problems in obese people. Despite their benefits, only a fraction of eligible Americans use them due to cost and lack of health coverage. For instance, Wegovy's monthly price without insurance can exceed $1,000.

Currently, around 40% of American adults are obese, but only about 10% use these drugs. Researchers estimated that even in this low-use scenario, about 8,500 deaths are prevented yearly. However, if these drugs were more accessible, that number could jump to 42,000 deaths prevented each year. But access isn't the only challenge. Side effects like diarrhea and vomiting can be a turn-off, and not everyone responds well to the treatment. Moreover, the demand for these drugs often outstrips supply, leading to shortages and a black market for cheaper, less safe versions. The study highlights the need for a multifaceted approach to ensure eligible people can access these lifesaving drugs. This includes adjusting drug prices to reflect manufacturing costs and expanding production capacity.

Actions